Document Detail

AAV-mediated overexpression of human α7 integrin leads to histological and functional improvement in dystrophic mice.
MedLine Citation:
PMID:  23319059     Owner:  NLM     Status:  MEDLINE    
Duchenne muscular dystrophy (DMD) is a severe muscle disease caused by mutations in the DMD gene, with loss of its gene product, dystrophin. Dystrophin helps link integral membrane proteins to the actin cytoskeleton and stabilizes the sarcolemma during muscle activity. We investigated an alternative therapeutic approach to dystrophin replacement by overexpressing human α7 integrin (ITGA7) using adeno-associated virus (AAV) delivery. ITGA7 is a laminin receptor in skeletal and cardiac muscle that links the extracellular matrix (ECM) to the actin skeleton. It is modestly upregulated in DMD muscle and has been proposed to be an important modifier of dystrophic symptoms. We delivered rAAV8.MCK.ITGA7 to the lower limb of mdx mice through isolated limb perfusion (ILP) of the femoral artery. We demonstrated ~50% of fibers in the tibialis anterior (TA) and extensor digitorum longus (EDL) overexpressing α7 integrin at the sarcolemma following AAV gene transfer. The increase in ITGA7 in skeletal muscle significantly protected against loss of force following eccentric contraction-induced injury compared with untreated (contralateral) muscles while specific force following tetanic contraction was unchanged. Reversal of additional dystrophic features included reduced Evans blue dye (EBD) uptake and increased muscle fiber diameter. Taken together, this data shows that rAAV8.MCK.ITGA7 gene transfer stabilizes the sarcolemma potentially preserving mdx muscle from further damage. This therapeutic approach demonstrates promise as a viable treatment for DMD with further implications for other forms of muscular dystrophy.
Kristin N Heller; Chrystal L Montgomery; Paul Ml Janssen; K Reed Clark; Jerry R Mendell; Louise R Rodino-Klapac
Related Documents :
25092969 - Masseter muscle tension, chewing ability, and selected parameters of physical fitness i...
24278879 - The effect of mcconnell taping on vastus medialis and lateralis activity during squatti...
24878839 - Whole-body muscle mri to detect myopathies in non-extrapyramidal bent spine syndrome.
21705019 - Microvascular tissue oxygenation and oxidative metabolism changes in the pedicled latis...
18818909 - Combined effects of preceding muscle vibration and contraction on the tonic vibration r...
23131709 - Stimulation of the motor cortex and corticospinal tract to assess human muscle fatigue.
2262419 - Interactions between the beta-adrenergic agonist salbutamol and genotype on meat qualit...
16351889 - Myoseptal architecture of sarcopterygian fishes and salamanders with special reference ...
20501639 - Retraction.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2013-01-15
Journal Detail:
Title:  Molecular therapy : the journal of the American Society of Gene Therapy     Volume:  21     ISSN:  1525-0024     ISO Abbreviation:  Mol. Ther.     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-03-01     Completed Date:  2013-10-22     Revised Date:  2014-06-30    
Medline Journal Info:
Nlm Unique ID:  100890581     Medline TA:  Mol Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  520-5     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antigens, CD / genetics*,  metabolism
Dependovirus / genetics*
Disease Models, Animal
Dystrophin / genetics,  metabolism
Extracellular Matrix / metabolism
Gene Transfer Techniques
Genetic Therapy / methods
Genetic Vectors*
Integrin alpha Chains / genetics*,  metabolism
Mice, Inbred mdx
Muscle, Skeletal / metabolism,  physiopathology
Muscular Dystrophy, Duchenne / genetics,  physiopathology,  therapy*
Sarcolemma / genetics
Grant Support
Reg. No./Substance:
0/Antigens, CD; 0/Dystrophin; 0/Integrin alpha Chains; 0/integrin alpha7

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Differential type I interferon-dependent transgene silencing of helper-dependent adenoviral vs. aden...
Next Document:  DVC1-0101 to treat peripheral arterial disease: a Phase I/IIa open-label dose-escalation clinical tr...